Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Iprat...( Clinical trial data for Perforomi...),Health

Clinical trial data for Perforomist(TM) Solution presented at International CHEST Conference

PHILADELPHIA, Oct. 29 /PRNewswire-USNewswire/ -- Data from a Phase IIIb clinical trial demonstrate that Perforomist(TM) (formoterol fumarate) Inhalation Solution nebulized treatment provided prolonged bronchodilation and increased patient satisfaction compared to albuterol/ipratropium by metered-dose inhaler (MDI). These data were presented today in Philadelphia at CHEST 2008, the annual scientific assembly of the American College of Chest Physicians (ACCP).

Perforomist(TM) Solution was approved in 2007 by the FDA for long-term, twice-daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is the only FDA-approved nebulized formoterol fumarate.

Results from "In COPD, Nebulized Formoterol Fumarate Provides Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI" were presented in a poster session today.

"COPD patients in this study preferred twice-daily treatment with Perforomist(TM) Inhalation Solution nebulized formoterol fumarate over the albuterol/ipratropium combination MDI," said E. Rand Sutherland, M.D., M.P.H., National Jewish Health and lead clinical investigator. "These data provide physicians valuable information as they consider treatment options for COPD patients with moderate to severe forms of the disease."

This multicenter, randomized, open-label, two-period crossover study was conducted in 109 patients with moderate-to-severe COPD to evaluate the safety and efficacy of twice-daily Perforomist(TM) Inhalation Solution, nebulized FFIS, compared to albuterol/ipratropium MDI four times daily, as well as patient satisfaction and treatment preference. Efficacy was assessed by spirometry at the start and end of each two-week period, the transition dyspnea index, and a treatment sa
'/>"/>